Meyka AI API is live for developers.Start building.
Advertisement
ImmunityBio, Inc.

ImmunityBio, Inc. (IBRX) Stock Overview

Explore ImmunityBio, Inc.’s financial performance, market position, analyst ratings, and future outlook.

IBRXNASDAQ
HealthcareBiotechnology
$6.92
$0.37(5.08%)
U.S. Market opens in 56h 4m
Advertisement

ImmunityBio, Inc. (IBRX)

Meyka AI Score

Z

Key Financials

Market Cap7.2B
P/E Ratio-8.23
EPS (TTM)$-0.85
ROE1.39%
Fundamental Analysis

AI Price Forecasts

1 Month$8.16
3 Months$10.42
1 Year Target$4.76

IBRX Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of ImmunityBio, Inc. (IBRX) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 39.85, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $4.76.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -8.23 and a market capitalization of 7.2B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
-5.08%
5-Day Change
-9.54%
1-Month Change
-8.71%
3-Month Change
-22.77%
6-Month Change
202.18%
Year-to-Date (YTD) Change
249.49%
1-Year Change
138.62%
3-Year Change
148.03%
5-Year Change
-55.06%
All-Time (Max) Change
-80.02%

Contact Information

858 633 0300
3530 John Hopkins Court, San Diego, CA, 92121

Company Facts

671 Employees
IPO DateJul 28, 2015
CountryUS
Actively Trading

Frequently Asked Questions